The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial

Lewis J. Rubin, MD; Jessica Mendoza, BSN; Michele Hood, BSPh; Michael McGoon, MD; Robyn Barst, MD; William B. Williams, MD; Jane Hall Diehl, MS; James Crow, PhD; and Walker Long, MD
[+] Article, Author, and Disclosure Information

Requests for Reprints: Lewis J. Rubin, MD, University of Maryland School of Medicine, 10 South Pine Street, Room 8-00, Baltimore, MD 21201.

Current Author Addresses: Dr. Rubin and Ms. Mendoza and Ms. Hood: University of Maryland Hospital, 10 South Pine Street, Baltimore, MD 21201.

Dr. McGoon: Mayo Clinic, W16A, Cardiovascular Division, 200 First Street, S.W., Rochester, MN 55905.

Dr. Barst: Columbia University College of Physicians and Surgeons, New York, NY 10032.

Dr. Williams: Maine Medical Center, 22 Bramhall Street, Portland, ME 04102.

Ms. Diehl and Drs. Crow and Long: Burroughs Wellcome Company, Research Triangle Park, NC 27709.

© 1990 American College of PhysiciansAmerican College of Physicians

Ann Intern Med. 1990;112(7):485-491. doi:10.7326/0003-4819-112-7-485
Text Size: A A A

Study Objective: To determine the efficacy of continuous intravenous infusion of prostacyclin (epoprostenol) in primary pulmonary hypertension.

Design: Randomized trial with 8-week treatment periods and nonrandomized treatment for up to 18 months.

Setting: Four referral centers.

Patients: Sequential sample of 24 patients with primary pulmonary hypertension. Nineteen patients completed the study. Four patients died and one left the study because of adverse effects (pulmonary edema).

Interventions: Continuous intravenous prostacyclin administered by portable infusion pump at doses determined by acute responses during baseline catheterization in ten patients. Nine patients were treated with anticoagulants, oral vasodilators, and diuretics.

Measurements and Main Results: Starting with a baseline value for total pulmonary resistance of 21.6 units, there was a decrease of 7.9 units (95% CI, -13.1 to -2.2; P = 0.022) in the prostacyclin-treated group after 8 weeks; there was virtually no change in the conventional therapy group (from 20.6 to 20.4 units, not significant). Six of ten prostacyclin-treated patients who completed the 8-week study period had reductions in mean pulmonary artery pressure of greater than 10 mm Hg, whereas only one of nine in the conventional treatment group had a similar response (P = 0.057). Nine patients receiving prostacyclin for up to 18 months have persistent hemodynamic effects, although dose requirements have increased with time. Complications have been attributable to the drug delivery system.

Conclusions: Prostacyclin produces substantial and sustained hemodynamic and symptomatic responses in severe primary pulmonary hypertension and may be useful in the management of some patients with this disease.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.